Product Overview

AOP Orphan's focus is on rare and special diseases. The portfolio comprises products in the following therapeutic areas: HematoOncology, Cardiology & Pulmonology, Neurology and Metabolic Disorders and Intensive Care. AOP Orphan’s strategic goal is to constantly deliver new treatment options with respect to rare and special diseases. 

HematoOncology

Anagrelide AOP

Anagrelide AOP is indicated in Essential Thrombocythemia for the reduction of elevated platelet counts and associated clinical symptoms in at high risk patients

Drug Facts
Active Ingredient
Anagrelide
HematoOncology

BESREMi®

BESREMi® is indicated as monotherapy in adults for the treatment of Polycythaemia Vera without symptomatic splenomegaly.

Drug Facts
Active Ingredient
Ropeginterferon alfa-2b
HematoOncology

Canemes®

Canemes® is indicated for the treatment of nauseas and vomiting in adults who do not adequately respond to other anti-emetic treatment options.

Drug Facts
Active Ingredient
Nabilone
HematoOncology

Thromboreductin®

Thromboreductin® is indicated for the reduction of elevated platelet counts and associated clinical symptoms in at high risk essential thrombocythemia patients

Drug Facts
Active Ingredient
Anagrelide